Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Tandem Diabetes Care has received an average consensus rating of "Hold" from fifteen brokerages, with eleven analysts recommending a hold and four analysts suggesting a buy.
• The company's most recent earnings report indicated a loss of ($0.48) EPS, missing estimates, but revenue grew by 8.5% year-over-year to $240.68 million.
• Significant changes in insider ownership were observed, with CEO John F. Sheridan purchasing 10,000 shares at an average price of $10.23 per share, indicating confidence in the company's future.

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) have been assigned an average recommendation of "Hold" from the fifteen brokerages that are covering the stock, Marketbeat.com reports. Eleven research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $22.4667.

Several analysts have recently commented on TNDM shares. Wall Street Zen cut shares of Tandem Diabetes Care from a "hold" rating to a "sell" rating in a research note on Saturday, June 21st. Canaccord Genuity Group set a $24.00 target price on shares of Tandem Diabetes Care and gave the stock a "buy" rating in a research note on Thursday, August 7th. Wells Fargo & Company reduced their target price on shares of Tandem Diabetes Care from $20.00 to $13.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. UBS Group reduced their target price on shares of Tandem Diabetes Care from $20.00 to $17.00 and set a "neutral" rating for the company in a research note on Thursday, August 7th. Finally, Royal Bank Of Canada cut their price target on shares of Tandem Diabetes Care from $45.00 to $25.00 and set an "outperform" rating for the company in a report on Thursday, August 7th.

Tandem Diabetes Care Stock Up 1.5%

TNDM stock opened at $12.58 on Monday. Tandem Diabetes Care has a one year low of $9.98 and a one year high of $47.60. The stock has a market capitalization of $850.03 million, a PE ratio of -4.07 and a beta of 1.45. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.88 and a current ratio of 2.44. The company has a fifty day moving average of $14.07 and a 200-day moving average of $18.09.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its earnings results on Wednesday, August 6th. The medical device company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.08). Tandem Diabetes Care had a negative return on equity of 65.40% and a negative net margin of 20.51%.The firm had revenue of $240.68 million during the quarter, compared to analyst estimates of $238.39 million. During the same quarter last year, the business posted ($0.47) EPS. The firm's revenue was up 8.5% on a year-over-year basis. As a group, analysts expect that Tandem Diabetes Care will post -1.68 EPS for the current year.

Insider Transactions at Tandem Diabetes Care

In related news, CEO John F. Sheridan purchased 10,000 shares of the business's stock in a transaction dated Monday, August 11th. The stock was acquired at an average price of $10.23 per share, for a total transaction of $102,300.00. Following the acquisition, the chief executive officer directly owned 106,327 shares of the company's stock, valued at $1,087,725.21. This trade represents a 10.38% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Leigh Vosseller purchased 13,720 shares of the business's stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $10.89 per share, with a total value of $149,410.80. Following the acquisition, the chief financial officer directly owned 25,580 shares in the company, valued at approximately $278,566.20. This represents a 115.68% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.90% of the company's stock.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of large investors have recently made changes to their positions in the stock. Sessa Capital IM L.P. purchased a new position in shares of Tandem Diabetes Care in the 1st quarter valued at about $85,574,000. GW&K Investment Management LLC raised its position in Tandem Diabetes Care by 34.9% during the first quarter. GW&K Investment Management LLC now owns 2,863,987 shares of the medical device company's stock worth $54,874,000 after acquiring an additional 740,499 shares during the last quarter. Hood River Capital Management LLC raised its position in Tandem Diabetes Care by 10.9% during the second quarter. Hood River Capital Management LLC now owns 2,564,978 shares of the medical device company's stock worth $47,811,000 after acquiring an additional 252,934 shares during the last quarter. Paradice Investment Management LLC raised its position in Tandem Diabetes Care by 7.1% during the second quarter. Paradice Investment Management LLC now owns 1,767,179 shares of the medical device company's stock worth $32,940,000 after acquiring an additional 117,272 shares during the last quarter. Finally, Stephens Investment Management Group LLC raised its position in Tandem Diabetes Care by 1.8% during the second quarter. Stephens Investment Management Group LLC now owns 1,737,769 shares of the medical device company's stock worth $32,392,000 after acquiring an additional 30,854 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.